Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin

104Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Thrombocytopenia developing in the course of chemotherapy for malignant disease is usually attributed to drug-induced marrow suppression and/or marrow replacement by tumor. We describe two patients who developed severe thrombocytopenia and hemorrhagic symptoms while being treated with oxaliplatin, 5-fluorouracil, and leukovorin for metastatic colon cancer in whom platelet destruction appears to have been caused by oxaliplatin-dependent antibodies specific for the platelet glycoprotein IIb/IIIa complex (αIIb/ β3 integrin). Drug-induced immune thrombocytopenia (DITP) should be considered in patients who experience a sudden, isolated drop in platelet levels while being treated with chemotherapeutic agents, especially when adequate numbers of megakaryocytes are present In the bone marrow. © 2006 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Curtis, B. R., Kaliszewski, J., Marques, M. B., Saif, M. W., Nabelle, L., Blank, J., … Aster, R. H. (2006). Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. American Journal of Hematology, 81(3), 199–201. https://doi.org/10.1002/ajh.20516

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free